Applied BioCode Corporation reported earnings results for the third quarter and nine months ended September 30, 2022. For the third quarter, the company reported sales was TWD 107.77 million compared to TWD 58.78 million a year ago. Net loss was TWD 44.11 million compared to TWD 61.1 million a year ago. Basic loss per share from continuing operations was TWD 0.54 compared to TWD 0.75 a year ago. Diluted loss per share from continuing operations was TWD 0.54 compared to TWD 0.75 a year ago.
For the nine months, sales was TWD 269.57 million compared to TWD 210.44 million a year ago. Net loss was TWD 149.52 million compared to TWD 139.73 million a year ago. Basic loss per share from continuing operations was TWD 1.83 compared to TWD 1.71 a year ago. Diluted loss per share from continuing operations was TWD 1.83 compared to TWD 1.71 a year ago.